Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from SSY Group ( (HK:2005) ).
SSY Group Limited has announced significant progress in its innovative drug development projects. The company’s SYN045 tablets, designed to treat pulmonary hypertension, have shown promising results in Phase I clinical trials, with improvements in safety and tolerability. The company plans to advance to Phase IIa trials to further explore efficacy and safety. Additionally, SSY Group is developing new drugs targeting epilepsy and pain treatment, with ongoing compound screening and toxicity assessments. The company is committed to accelerating its drug development efforts and keeping stakeholders informed of its progress.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development of innovative drugs. The company is engaged in the creation of new chemical drugs and improved formulations, with a market focus on treatments for pulmonary hypertension, epilepsy, and diabetic peripheral neuropathic pain.
YTD Price Performance: -18.67%
Average Trading Volume: 12,616,505
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.29B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.